Monika Šatánková
Masaryk University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Monika Šatánková.
Tumor Biology | 2017
Ondrej Fiala; Miloš Pešek; Jana Skřičková; Vitezslav Kolek; František Salajka; Marcela Tomíšková; Monika Šatánková; Juraj Kultan; Jana Kulísková; Martin Svaton; M. Hrnčiarik; Karel Hejduk; Renata Chloupková; Ondrej Topolcan; Helena Hornychova; Markéta Nová; Aleš Ryška; Jindrich Finek
Pemetrexed is an antifolate cytostatic agent targeting several folate-dependent enzymatic pathways, widely used in the treatment of locally advanced or metastatic stage non-small cell lung cancer. Aside from the non-squamous histology, there is still no available molecular biomarker predicting treatment efficacy of pemetrexed-based chemotherapy. The aim of our retrospective study was to evaluate the association of thyroid transcription factor 1 expression with outcome of a large cohort of patients with non-squamous non-small cell lung cancer treated with pemetrexed. We retrospectively analysed clinical data of 463 patients with advanced-stage non-small cell lung cancer (IIIB or IV) treated with pemetrexed-based chemotherapy. Thyroid transcription factor 1 expression was assessed using indirect immunohistochemical detection in formalin-fixed paraffin-embedded tumour tissue at the time of diagnosis. Thyroid transcription factor 1 expression was detected in the tumour tissue from 76.0% of patients, and tumours from 24.0% of patients were thyroid transcription factor 1 negative. The median progression-free survival and overall survival for patients with thyroid transcription factor 1 positive tumours were 4.8 and 11.8 months compared to 2.8 and 8.3 months for those with thyroid transcription factor 1 negative tumours (p = 0.001 and p < 0.001). The multivariable Cox proportional hazards model revealed that thyroid transcription factor 1 expression was significantly associated with progression-free survival (hazard ratio = 1.57, p < 0.001) and also with overall survival (hazard ratio = 1.73, p < 0.001). In conclusion, the results of the conducted retrospective study suggest that the thyroid transcription factor 1 expression was independently associated with progression-free survival and overall survival in patients with advanced-stage non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy.
Klinicka Onkologie | 2018
Miloš Pešek; Jana Skřičková; Vítězslav Kolek; Monika Šatánková; Leona Koubková; Jaromír Roubec; Renata Chloupková; Marketa Cernovska; Andrea Benejová; Juraj Kultan; M. Hrnčiarik; Milada Zemanová; Marek Konečný; Helena Čouková; Martin Svatoň
BACKGROUND Patients with advanced anaplastic lymphoma kinase (ALK) -positive non-small cell lung cancer (NSCLC) may gain significant benefit from treatment with the first-generation ALK inhibitor crizotinib. This study investigated the effects of crizotinib in advanced ALK-positive NSCLC patients via analyzing data submitted to the TULUNG registry by pneumo-oncology centers in the Czech Republic. PATIENTS AND METHODS We analyzed the data of 60 NSCLC patients submitted to the TULUNG registry by pneumo-oncology centers who had ALK translocation confirmed by fluorescence in situ hybridization and complete data records from 2011 to 2017. RESULTS The median age of patients was 58 years. A total of 53% of patients were men, 90% had adenocarcinomas, 61.7% were smokers or ex-smokers, and 65% had a performance status of 0. Upon initiation of crizotinib therapy, most patients were at stage IV (88.3%) and the remainder were at stage IIIA or IIIB. Crizotinib was the second-line therapy in 71.7% of patients. A total of 20% of patients suffered side effects, while 11.7% suffered grade 3 and 4 adverse effects. A total of, 6.7, 25, 21.7, and 25% of patients displayed a complete response, a partial response, stable disease, and progressive disease, resp. Progression-free survival (PFS) was 5.8 months. Overall survival (OS) was 27.9 months from the initiation of the first-line therapy and 12.6 from the initiation of crizotinib therapy. PFS and OS were longer among nonsmokers and ex-smokers than among smokers (PFS, 9.7 vs. 5.8 vs. 3.8 months, p = 0.029; OS, 26.8 vs. 15.3 vs. 7.0 months, p = 0.015). CONCLUSION Targeted crizotinib therapy is well tolerated and has significant benefit in patients with advanced ALK-positive NSCLC. Although international guidelines recommend that crizotinib is only used as a first-line therapy, it is used as a second-line and higher-line therapy in the Czech Republic. Clinical studies provide evidence that targeted therapy elicits better effects and less toxicity than routine chemotherapy. Key words: ALK translocation - crizotinib - targeted biological therapy - tyrosine kinase inhibitors This work was supported by AZV grant No. 17- 30748A. The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study. The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers. Submitted: 17. 1. 2018 Accepted: 20. 2. 2018.
Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti | 2017
Monika Šatánková; Kristián Brat; Marcela Tomíšková; Blanka Robešová; Jana Skřičková
BACKGROUND Squamous cell carcinoma of the lung (SCC) represents cca 30-40% of new cases of non-small cell lung cancer (NSCLC) in the Czech Republic. The tyrosine kinase inhibitor erlotinib is indicated as a 1st line treatment for patients with locally advanced and metastatic disease and activating mutations in endothelial growth factor receptor (EGFR), or as a 2nd or 3rd line treatment in EGFR-negative NSCLC patients after chemotherapeutic failure. OBSERVATION We present three case reports of patients with SCC treated with erlotinib as a 2nd or 3rd line of treatment. All patients were verified by histological analysis of tumor samples. EGFR mutation status was negative in one patient, while the other samples were not suitable for genetic screening. RESULTS The therapeutic response to erlotinib lasted for 68, 40, and 13 months, resp. The patient with the longest therapeutic response (patient no. 1) is still continuing erlotinib treatment (as of December 2016). The overall survival of the two patients who died was 50 and 43 months, resp. One patient died of an unknown cause with no signs of progression of the disease on CT scans. The other patient died of terminal progression of the oncological disease. All three patients experienced major therapeutic benefit from erlotinib treatment as shown by the long periods of progression-free survival and prolonged overall survival. CONCLUSION The three case reports demonstrate that erlotinib may be effective as a 2nd or 3rd line treatment in patients with SCC, especially in patients with limited alternative anticancer treatment options.Key words: non-small cell lung cancer - squamous cell carcinoma - erlotinib - treatment - tyrosine kinase inhibitor The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study. The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.Submitted: 5. 8. 2016Accepted: 14. 12. 2016.
Vnitřní lékařství | 2018
Monika Šatánková; Kristián Brat; Zdeněk Merta; Miloš Šteffl
Archive | 2017
Jana Skřičková; Renata Chloupková; Zbyněk Bortlíček; Karel Hejduk; Miloš Pešek; Vítězslav Kolek; Ivona Grygárková; Leona Koubková; Marketa Cernovska; Marcela Tomíšková; Jaromír Roubec; Libor Havel; František Salajka; M. Hrnčiarik; Milada Zemanová; Monika Šatánková; Andrea Benejová; Dimka Sixtová; M. Marel; H. Čoupková; J. Krejčí; P. Opálka
Archive | 2017
Monika Šatánková; Kristián Brat; Zdeněk Merta
Archive | 2017
Jana Skřičková; Renata Chloupková; Marek Konečný; Milan Pešek; Petr Zatloukal; Vítězslav Kolek; František Salajka; M. Hrnčiarik; Leona Koubková; Marcela Tomíšková; Y. Grygárková; Libor Havel; Milada Zemanová; Dimka Sixtová; Jaromír Roubec; Leona Čoupková; Marketa Cernovska; Petr Opálka; J. Krejčí; Monika Šatánková; Andrea Benejová; M. Marel; Martina Vasakova
Archive | 2017
Vítězslav Kolek; M. Marel; D. Rakita; Jana Skřičková; Monika Šatánková; Zuzana Tóthová; Marketa Cernovska; Libor Havel; K. Hrdá; Martin Svatoň; M. Hrnčiarik; M. Jiroušek; S. Losse; O. Fišer; Petr Jakubec; Juraj Kultan; P. Bálint
Archive | 2017
Jana Skřičková; Renata Chloupková; Zbyněk Bortlíček; Karel Hejduk; Petr Brabec; Ladislav Dušek; Miloš Pešek; Vítězslav Kolek; Ivona Grygárková; Leona Koubková; Marketa Cernovska; Marcela Tomíšková; Jaromír Roubec; Libor Havel; František Salajka; M. Hrnčiak; Milada Zemanová; Monika Šatánková; Andrea Benejová; Dimka Sixtová; M. Merel; J. Krejčí; P. Opálka; H. Čoupková
Archive | 2017
Jana Skřičková; Renata Chloupková; Zbyněk Bortlíček; Karel Hejduk; Miloš Pešek; Vítězslav Kolek; Ivona Grygárková; Leona Koubková; Marketa Cernovska; Marcela Tomíšková; J. Roubek; L. Havek; František Salajka; M. Hrnčiarik; Milada Zemanová; Monika Šatánková; Andrea Benejová; Dimka Sixtová; M. Marel; H. Čoupková; J. Krejčí; P. Opálka